
| Location | Burlington, MA |
Position Summary
The Senior Director, Medical Affairs (Strategy) will be a key leader responsible for developing and executing the Medical Affairs strategy across the portfolio, with an initial focus on canvuparatide as the organization advances toward commercialization. This role will provide strategic and operational leadership across scientific communications, evidence generation, publication planning, medical education, and key opinion leader (KOL) engagement, ensuring medical excellence throughout launch preparation and beyond.
Partnering closely with Clinical Development, Commercial, Regulatory, and other cross-functional teams, the Senior Director will help shape the medical voice of the organization and translate scientific insights into actionable strategies. For earlier-stage programs, the role will provide targeted Medical Affairs support, including publication strategy, select KOL engagement, and advisory board activities aligned with program stage and business priorities. This position requires strong scientific credibility, strategic leadership, and the ability to thrive in a dynamic, growth-oriented environment.
Key Responsibilities
Education & Qualifications
Travel
You will be expected to travel periodically based on the needs of the business to the extent requested by the Company, including attendance at Together Weeks, Together Days, and functional meetings as requested by the Company.
Company Overview:
MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company's pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism preparing for Phase 3 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development and MBX 5765 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.
EEO Statement:
MBX Biosciences is an Equal Opportunity Employer and is committed to treating all applicants fairly without discrimination. We welcome applications from all individuals, regardless of race, national origin, gender, age, physical characteristics, social origin, disability, union membership, religion, family status, pregnancy, sexual orientation, gender identity, gender expression or any unlawful criterion under applicable law.





